Markus Rehm


Affiliation: University of Stuttgart
Country: Germany


  1. Podder B, Guttà C, Rožanc J, Gerlach E, Feoktistova M, Panayotova Dimitrova D, et al. TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma. Cell Death Differ. 2019;: pubmed publisher
    ..Overall, our results therefore demonstrate that TAK1 suppresses the susceptibility to RIPK1-dependent cell death and that high expression of TAK1 indicates an increased risk for disease progression in melanoma. ..
  2. Skoko J, Rožanc J, Charles E, Alexopoulos L, Rehm M. Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma. BMC Cell Biol. 2018;19:28 pubmed publisher
    ..Loss of p53 phosphorylation might be an interesting candidate for a kinetic marker of dasatinib responsiveness in melanoma, pending more comprehensive validation in future studies. ..
  3. Lincoln F, Imig D, Boccellato C, Juric V, Noonan J, Kontermann R, et al. Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism. Cell Death Dis. 2018;9:1112 pubmed publisher
  4. Crawford N, Salvucci M, Hellwig C, Lincoln F, Mooney R, O Connor C, et al. Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711. Cell Death Differ. 2018;25:1952-1966 pubmed publisher
  5. Hantusch A, Das K, García Sáez A, Brunner T, Rehm M. Bax retrotranslocation potentiates Bcl-xL's antiapoptotic activity and is essential for switch-like transitions between MOMP competency and resistance. Cell Death Dis. 2018;9:430 pubmed publisher
    ..Our results therefore identify Bax retrotranslocation by Bcl-xL as an indispensable component of the molecular switch by which Bcl-2 family members govern cellular death decisions. ..